The Goal: To protect the surgical investment and provide the hormonal support that surgery alone might lack over the long term
7,11,17 Apixaban 2.5 mg twice daily can be used to prevent VTE in patients undergoing hip or knee arthroplasty, 8,9 while dabigatran (110 mg first day, followed by 220 mg once daily) has been accepted for VTE prophylaxis after only hip surgery.10 Regarding high-risk ambulatory patients with cancers, low-intensity apixaban (2.5 mg twice daily)18 and rivaroxaban (10 mg once daily) 19 have been considered for primary prevention of VTE by some guidelines 20 but not thus far added to the FDA labels
doi: 10.3389/fsci.2025.1441297 Received 30 May 2024 Accepted 15 January 2025 Published 25 March 2025 Volume 3 - 2025 Edited by Jon Storm-Mathisen, University of Oslo, Norway Reviewed by Richard B
Choose an existing saved option or add a new one in your account
When you compare this to Mounjaro, where clinical trials have shown patients can lose up to 22.5% of their body weight after 72 weeks, the difference in the level of evidence is significant